Welcome to

United Therapeutics Global Medical Affairs

This website is a resource intended for U.S. healthcare professionals only. This site is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. United Therapeutics does not provide medical advice. It is the healthcare professional’s responsibility to use independent clinical judgment when making clinical decisions for individual patients.

This website may include information that has not been approved by the U.S. Food and Drug Administration. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling.

Are you a U.S. Healthcare professional?

You are now leaving the UnitherMedAffairs.com website.

This link will take you to a site maintained by a third party who is solely responsible for the site’s content. Click CONTINUE to proceed or CLOSE to return to UnitherMedAffairs.com.

CONTINUE

The following information is limited to United Therapeutics sponsored studies. Information is not intended to offer recommendations for any administration, indication, dosage, or other use inconsistent with approved prescribing information.

►

Filter

Conference

All

Advances in Neuroblastoma Research 2018

AMCP Annual Meeting 2018

AMCP Nexus 2018

American Association for Cancer Research 2019

ASCO Annual Meeting 2018

ATS International Conference 2018 - 2019

CHEST Annual Meeting 2018

European Lung Cancer Congress 2018

ISHLT Annual Meeting & Scientific Sessions 2019

ISPOR Conference 2018

PVRI Annual World Congress of PVD 2019

UT Product

All

Orenitram® (treprostinil) Extended-Release Tablets

Remodulin® (treprostinil) Injection

Tyvaso® (treprostinil) Inhalation Solution

Unituxin® (dinutuximab) Injection

file icon
Borg Dyspnea Score Adjusted Six Minute Walk Distance in Pulmonary Arterial Hypertension Clinical Trials
file icon
Treatment with Oral Treprostinil is Associated with Improved Survival in Pulmonary Arterial Hypertension Participants from the FREEDOM-EV Study
file icon
Treatment with oral treprostinil significantly delays time to clinical worsening in patients with pulmonary arterial hypertension – results from the phase 3, randomized, double-blind, placebo-controlled FREEDOM-EV study
file icon
Identifying patients with pulmonary arterial hypertension (PAH) using administrative claims algorithms
file icon
Early versus late initiation of treatment with prostacyclin-class therapy in patients with Pulmonary Arterial Hypertension (PAH)
file icon
A real-world health insurance claims analysis of oral prostacyclin class therapy utilization and outcomes
file icon
Risk stratification Using Noninvasive Parameters: A post hoc analysis of the TRIUMPH and FREEDOM-C2 studies
file icon
The economic burden of pulmonary hypertension among patients with chronic obstructive pulmonary disease and interstitial lung disease
file icon
Real-World Dosing Characteristics of Parenteral Treprostinil
file icon
Risk Scores and Risk-based Stratification of Clinical Worsening Events in PAH Patients Treated with Oral Treprostinil in FREEDOM-EV
file icon
Cytokine Profile and Association with Toxicities and Outcome of High-Risk Neuroblastoma Treated with Dinutuximab Immunotherapy on COG ANBL0931
file icon
Phase II Trial of Irinotecan/Temozolomide with Dinutuximab/GMCSF (I/T/DIN/GMCSF) in Relapsed/Refractory Neuroblastoma: A Report from The Children’s Oncology Group (COG)
file icon
Dinutuximab binds specifically to Disialoganglioside-2
file icon
Treatment with prostacyclins delays and reduces hospital readmissions among PAH patients
file icon
88P Feasibility of outpatient dinutuximab (D) and irinotecan (I) for second-line treatment of relapsed or refractory small cell lung cancer (RR SCLC): Part 1 of an open-label, randomized, phase 2/3 study
file icon
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction—Design of Study TDE-HF-301
file icon
Transition to Oral Treprostinil from Parenteral or Inhaled Treprostinil or as Add-on Therapy in Pediatric Subjects with Pulmonary Arterial Hypertension
file icon
A Two-Part, Open-Label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan versus Irinotecan for Second-Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer
file icon
The Effect of Treprostinil Dose on Time to All Cause and Pulmonary Arterial Hypertension-Related Hospitalizations
file icon
The relationship between non-invasive endpoints and long-term outcomes in pulmonary arterial hypertension: six-minute walk, functional class and brain natriuretic peptide
file icon
Predicting adherence to oral treprostinil in patients with pulmonary arterial hypertension
file icon
Treatment with prostacyclins reduces hospital readmissions among patients with pulmonary arterial hypertension
file icon
The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: a meta-analysis
file icon
Combination therapy reduces hospitalizations in patients with pulmonary arterial hypertension
file icon
Novel analysis of treprostinil dose-response relationship using weight-normalized dosing
file icon
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension Due to Parenchymal Lung Disease (Study RIN-PH-201)
file icon
Increasing treprostinil dose reduces annual hospitalization rates and consequent costs in patients with pulmonary arterial hypertension
file icon
Stability of treprostinil with diluents and medications
file icon
Pharmacokinetics of oral treprostinil in children with pulmonary arterial hypertension
file icon
Dosing characteristics of oral treprostinil in real-world clinical practice